Jiangsu Vcare’s VC004 Joins NMPA’s SPARK Oncology Program
The Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has officially...
Vcare PharmaTech
Huadong Medicine Inks Exclusive Deal for JAK1 Inhibitor VC005 in China
On August 12, 2025, China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its exclusive...
Jiangsu Vcare PharmaTech’s VC004 NDA Accepted for Review by China’s NMPA
China-based Jiangsu Vcare PharmaTech Co., Ltd announced that its New Drug Application (NDA) for VC004...
Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing
Jiangsu Vcare PharmaTech Co., Ltd., a China – based high – tech pharmaceutical company, has...
Jiangsu Vcare Pharma Partners with Geneseeq Technology to Develop Companion Diagnostic for NTRK Inhibitor
Jiangsu Vcare PharmaTech Co., Ltd, a biopharmaceutical company based in China, has entered into a...
Jiangsu Vcare PharmaTech Submits NDA to US FDA for Vicagrel, a P2Y12 Receptor Antagonist
Jiangsu Vcare PharmaTech Co., Ltd, a Chinese pharmaceutical company, has submitted a New Drug Application...
Jiangsu Vcare PharmaTech Raises RMB 200 Million in Series B Financing Round
China-based Jiangsu Vcare PharmaTech Co. Ltd has reportedly raised over RMB 200 million (USD 28.67...